RE: Podcast6 Sep 2019 16:38
Aim4,
I sold out because the answer I got from Dr Gooding did not encourage me as I have already taken great pains to explain.
Excerpt from RNS Number : 0408ZNuformix PLC14 May 2019:
Prior to entry to the clinic, Nuformix carried out an additional studies to furthervalidate it's prototype NXP001 cocrystal formulations. NSB's acceptance ofsuccess in this work announced today brings the total milestone paymentsfrom NSB to £1 million, with a further £2 million payment due dependant onrelative human bioavailability results, as per the agreement for NXP001marketing and distribution in China.Commenting on the news, Dr Dan Gooding, CEO of Nuformix, said:"We're delighted to have reached this second pre-clinical milestone. The datagenerated was not only sufficient to trigger a second payment of £500k withNewsummitBio, but also gave us tremendous confidence to make the next stepinto human studies. We look forward to sharing human data very soon andcontinue to work closely with NSB, such is their commitment to thecommercialisation of NXP001 and its understanding of the commercialopportunity in China. Milestone revenues continue to validate Nuformix'sbusiness model and its commitment to reinvest early revenues back into R&D,avoiding further fund-raising at this stage whilst maximising the potential valueof its cocrystal platform.